By Galen Care Partners on Wednesday, 12 April 2017
Category: Galen Care Partners News

Tolvaptan Offers Sustained Slowing of Renal Function Decline in ADPKD

Open-label extension study confirms disease-modifying effect on eGFR, but not total kidney volume growth.
Original link
Leave Comments